Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cozaar, Atacand Labels Include Class Rhabdomyolysis Risk

Executive Summary

Labeling for Merck's Cozaar (losartan) and AstraZeneca's Atacand (candesartan) includes language describing a class risk for rhabdomyolysis among angiotensin II receptor blockers

You may also be interested in...



ARB rhabdomyolysis labeling

All seven angiotensin II receptor blocker manufacturers have either added class labeling for rhabdomyolysis risk or are currently updating labeling, FDA said March 10. One manufacturer had put the labeling update on hold pending receipt of additional background information from FDA (1"The Pink Sheet" March 7, 2004, p. 14)...

ARB rhabdomyolysis labeling

All seven angiotensin II receptor blocker manufacturers have either added class labeling for rhabdomyolysis risk or are currently updating labeling, FDA said March 10. One manufacturer had put the labeling update on hold pending receipt of additional background information from FDA (1"The Pink Sheet" March 7, 2004, p. 14)...

Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure

AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel